ChromaCode, a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, announced a strategic investment from corporate venture capital fund Shimadzu Future Innovation Fund L.P., with general partner Global Brain Corporation. This funding will support ChromaCode’s continued development of its HDPCR technology to deliver high quality, faster, less expensive diagnostic tools that address unmet clinical needs in disease detection and monitoring.
“We are excited to welcome the Shimadzu Future Innovation Fund as a strategic investor. We believe that the genomic assay portfolio we are building for multiple clinically actionable biomarkers has the potential to help millions of patients across the world,” said CEO Mark McDonough. “Our HDPCR platform, powered by cloud-based analytics, provides scalable solutions that are fast, widely accessible and cost effective. This financing will help us accelerate the development of new solutions that will enable our laboratory customers and our physician partners to help drive better outcomes for the patients that we all are privileged to serve.”
Yasuhiko Yurimoto, President & CEO at Global Brain Corporation, added, “We are proud to support ChromaCode and believe its novel HDPCR technology is an exciting addition to the Oncology marketplace and will have significant positive impacts on patients. Our investment bears witness to the encouraging progress made by ChromaCode in the diagnostics arena, and we look forward to future developments in their assays.”